One option is the MyProstateScore (MPS) test (LynxDx, Inc., Ann Arbor, MI), which combines urinary expression of prostate cancer antigen 3 (PCA3) and the TMPRSS2:ERG gene fusion (T2:ERG) with serum PSA to define the risk of GG ≥ 2 cancer [6]. Here, PCA3 is linked to cancer.